Link Silicon Valley
The fastest way to connect to the people, companies and capital of Silicon Valley
Free 30 Day Trial Account
Sign Up | Log In
Search
ACQUIRED COMPANY
 
My Lists

XenoPort  (Stock symbol: XNPT ) Acquired by Arbor Pharmaceuticals (2016 $ 467,000,000 )

3410 Central Expressway
Santa Clara, CA 95051
USA
(408)-616-7200
Website Company Summary Management Team
Board

Outside board: (May no longer be on the board) Per G. H. Lofberg (Pharma Capital Ventures Managing Director) Kenneth Nussbacher (Affymetrix CFO) William J. Rieflin (XenoPort Former President);  Wendell Wierenga (Ambit Biosciences EVP R&D) Catherine Friedman (Morgan Stanley Former Managing Director) Paul L. Berns (Allos Therapeutics President/CEO) Jeryl L. Hilleman (Accelrys Former CFO) Ernest Mario (Soleno Therapeutics CEO/Chairman) Dennis M Fenton (Amgen EVP Operations) John G. Freund (Skyline Ventures Managing Director)
Former outside board: Gary D. Tollefson (Orexigen Therapeutics CEO) Joel Kellman (GGV Capital Managing Partner);  Paul Goddard (Heron Therapeutics);  Robert Overell (Frazier & Company);  Bryan E. Roberts (Venrock Associates)
Company

Business description: XenoPort, Inc. is a biopharmaceutical company focused on developing and commercializing a portfolio of internally discovered product candidates for the potential treatment of neurological disorders. XenoPort is currently commercializing HORIZANT® (gabapentin enacarbil) Extended-Release Tablets in the United States and developing its novel fumaric acid ester product candidate, XP23829, as a potential treatment for patients with moderate-to-severe chronic plaque-type psoriasis and potentially for relapsing forms of multiple sclerosis. REGNITE® (gabapentin enacarbil) Extended-Release Tablets is being marketed in Japan by Astellas Pharma Inc. XenoPort has entered into a collaboration with the National Institute on Alcohol Abuse and Alcoholism for the development of HORIZANT as a potential treatment for AUD and has granted exclusive world-wide rights for the development and commercialization of its clinical-stage oral product candidate, arbaclofen placarbil, to Indivior PLC for all indications. XenoPort's pipeline of product candidates also includes a potential treatment for patients with idiopathic Parkinson's disease.
Capital

Rounds: 4
Recent Fundings: Nov 2012   Feb 2004
Capital raised: 147.4M
Last Round: 20.0M
Ownership: Acquired by Arbor Pharmaceuticals (2016 $ 467,000,000 )
Stock Symbol: XNPT
VCs include: Presidio PartnersSkyline VenturesVenrock AssociatesFrazierAndCompany;  Lombard Odier;  Arch Venture PartnersOrbiMed;  The Invus Group;  Lilly BioVentures;  NBM Bioventures
Corporate investors: Novartis Bioventures;  Lotus BioScience;  Eli Lilly BioVentures

Last Tweets


 

Last Mentions


Overview
Record updated: May 2016
Sector: Medical
Year Founded: 1999
Headcount: 101-150 as of Feb 2011
Rounds: 4
Recent Fundings: Nov 2012   Feb 2004
Capital Raised: 147.4M
Last Round: 20.0M
Ownership: Acquired by Arbor Pharmaceuticals (2016 $ 467,000,000 )
Stock Symbol: XNPT